Relation Between Atherosclerosis Risk Factors and Aspirin Resistance in a Primary Prevention Population

American Journal of Cardiology

Volumn 98, Issue 6, 2006, Pages 774-779

  Faraday, Nauder ^a   Becker, Diane M ^a   Yanek, Lisa R ^a   Herrera Galeano, Jesus Enrique ^a   Segal, Jodi B ^a   Moy, Taryn F ^a   Bray, Paul F ^b   Becker, Lewis C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; VON WILLEBRAND FACTOR;

ADULT; ANALYZER; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DETERMINATION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL LITERATURE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT ASSESSMENT; POPULATION RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYMPTOMATOLOGY; THERAPY RESISTANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT DURATION; URINALYSIS;

ADENOSINE DIPHOSPHATE; ADULT; ARACHIDONIC ACID; ASPIRIN; CORONARY ARTERIOSCLEROSIS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RISK FACTORS; THROMBOXANE B2; WHOLE BLOOD COAGULATION TIME;

EID: 33748052351     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.04.015     Document Type: Article

References (27)

1. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
2. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
3. Grundmann K., Jaschonek K., Kleine B., Dichgans J., and Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250 (2003) 63-66
4. Michelson A.D., Cattaneo M., Eikelboom J.W., Gurbel P., Kottke-Marchant K., Kunicki T.J., Pulcinelli F.M., Cerletti C., and Rao A.K. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 (2005) 1309-1311
5. Kim M.T., Hill M.N., Bone L.R., and Levine D.M. Development and testing of the Hill-Bone compliance to high blood pressure therapy scale. Prog Cardiovasc Nurs 15 (2000) 90-96
6. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K., and Topol E.J. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
7. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
8. American Diabetes Association. Clinical practice recommendations 2005. Diabetes Care 28 suppl (2005) S1-S79
9. NCEP Expert Panel. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
10. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
11. Liang K.W., and Zeger S.L. Regression analysis for correlated data. Annu Rev Public Health 14 (1993) 43-68
12. Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 110 (2003) 281-286
13. Belton O., Byrne D., Kearney D., Leahy A., and Fitzgerald D.J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 (2000) 840-845
14. Kirtikara K., Raghow R., Laulederkind S.J.F., Goorha S., Kanekura T., and Ballou L. Transcriptional regulation of cyclooxygenase-2 in the human microvascular endothelial cell line, HMEC-1: control by the combinatorial actions of AP2, NF-IL-6 and CRE elements. Mol Cell Biochem 203 (2000) 41-51
15. Maugeri N., Evangelista V., Piccardoni P., Dell'Elba G., Celardo A., de Gaetano G., and Cerletti C. Transcellular metabolism of arachidonic acid: increased platelet thromboxane generation in the presence of activated polymorphonuclear leukocytes. Blood 80 (1992) 447-451
16. Pfister S.L., Deinhart D.D., and Campbell W.B. Methacoline-induced contraction of rabbit pulmonary artery: role of platelet-endothelial transcellular thromboxane synthesis. Hypertension 31 (1998) 206-212
17. Karim S., Habib A., Levy-Toledano S., and Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 271 (1996) 12042-12048
18. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120
19. Cipollone F., Patrignani P., Greco A., Panara M.R., Padovano R., Cuccurullo F., Patrono C., Rebuzzi A.G., Liuzzo G., Quaranta G., and Meseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96 (1997) 1109-1116
20. Cattaneo M. Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24 (2004) 1980-1987
21. Altman R., Luciardi H.L., Muntaner J., and Herrera R.N. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?. Thromb J 2 (2004) 1-8
22. Gonzalez-Conejero R., Rivera J., Corral J., Acuna C., Guerrero J.A., and Vicente V. Biological assessment of aspirin efficacy on healthy individuals. Heterogeneous response or aspirin failure?. Stroke 36 (2005) 276-280
23. Favaloro E.J., Facey D., and Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 62 (1999) 165-174
24. Chakroun T., Gerotziafas G., Robert F., Lecrubier C., Samama M.M., Hatmi M., and Elalamy I. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 124 (2004) 80-85
25. Moake J.L., Turner N.A., Stathopoulos N.A., Nolasco L., and Hellums J.D. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 71 (1988) 1366-1374
26. Lee P.-Y., Chen W.-H., Ng W., Cheng X., Kwok J.Y.-Y., Tse H.-F., and Lau C.-P. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 118 (2005) 723-727
27. Cerletti C., Dell'Elba G., Manarini S., Pecce R., Di Castelnuovo A., Scorpiglione N., Feliziani V., and de Gaetano G. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may effect therapeutic outcomes. Clin Pharmacokinet 42 (2003) 1059-1070